Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

The Mutations of Topoisomerase Genes and Their Effect on Resistance to Fluoroquinolones in Extended-Spectrum β-Lactamase-Producing Escherichia coli

Roya Chegene Lorestani 1 , Alisha Akya 2 , * and Azam Elahi 1
Authors Information
1 MSc Student of Medical Microbiology, Department of Microbiology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 Associate Professor of Medical Microbiology, Nosocomial Infection Research Centre, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: February 2018, 13 (1); e57964
  • Published Online: February 24, 2018
  • Article Type: Research Article
  • Received: December 27, 2016
  • Revised: July 11, 2017
  • Accepted: February 20, 2018
  • DOI: 10.5812/jjnpp.57964

To Cite: Chegene Lorestani R, Akya A, Elahi A. The Mutations of Topoisomerase Genes and Their Effect on Resistance to Fluoroquinolones in Extended-Spectrum β-Lactamase-Producing Escherichia coli, Jundishapur J Nat Pharm Prod. 2018 ; 13(1):e57964. doi: 10.5812/jjnpp.57964.

Abstract
Copyright © 2018, Jundishapur Journal of Natural Pharmaceutical Products. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnote
References
  • 1. Barratt M, Avner ED, Harmon WE. Pediatric nephrology. 4th ed. Pensylvania: Lippincott Williams& Wilkinas; 2000. p. 158-67.
  • 2. Nicolle LE. Epidemiology of urinary tract infection. Infect Med. 2001;18:153-82.
  • 3. Apisarnthanarak A, Kiratisin P, Mundy LM. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2008;29(7):671-4. doi: 10.1086/588082. [PubMed: 18624669].
  • 4. Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008;168(17):1897-902. doi: 10.1001/archinte.168.17.1897. [PubMed: 18809817].
  • 5. Drago L, De Vecchi E, Mombelli B, Nicola L, Valli M, Gismondo MR. Activity of levofloxacin and ciprofloxacin against urinary pathogens. J Antimicrob Chemother. 2001;48(1):37-45. doi: 10.1093/jac/48.1.37. [PubMed: 11418511].
  • 6. Akya A, Najafi F, Sohrabi N, Vaziri S, Mansouri F, Azizi M, et al. The systematic review of quinolones resistance of escherichia coli isolated from urinary tract infections in Iran over the last ten years (2001-2011). Annu Res Rev Biol. 2015;6(4):234-44. doi: 10.9734/arrb/2015/12676.
  • 7. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001;7(2):337-41. doi: 10.3201/eid0702.700337. [PubMed: 11294736].
  • 8. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother. 2003;51(5):1109-17. doi: 10.1093/jac/dkg222. [PubMed: 12697644].
  • 9. Ambrozic Avgustin J, Keber R, Zerjavic K, Orazem T, Grabnar M. Emergence of the quinolone resistance-mediating gene aac(6')-Ib-cr in extended-spectrum-beta-lactamase-producing Klebsiella isolates collected in Slovenia between 2000 and 2005. Antimicrob Agents Chemother. 2007;51(11):4171-3. doi: 10.1128/AAC.01480-06. [PubMed: 17846136].
  • 10. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006;6(10):629-40. doi: 10.1016/S1473-3099(06)70599-0. [PubMed: 17008172].
  • 11. Yamane K, Wachino J, Suzuki S, Kimura K, Shibata N, Kato H, et al. New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob Agents Chemother. 2007;51(9):3354-60. doi: 10.1128/AAC.00339-07. [PubMed: 17548499].
  • 12. Frank T, Mbecko JR, Misatou P, Monchy D. Emergence of quinolone resistance among extended-spectrum beta-lactamase-producing Enterobacteriaceae in the Central African Republic: genetic characterization. BMC Res Notes. 2011;4:309. doi: 10.1186/1756-0500-4-309. [PubMed: 21867486].
  • 13. Krishnan S, Balasubramanian D, Raju BA, Lakshmi BS. Use of a naturally occurring codon bias for identifying topoisomerase mutations in ciprofloxacin resistant Escherichia coli using PCR and future prospects with other bacterial genera: A pilot study. Adv Biol Chem. 2012;2(4):366-71. doi: 10.4236/abc.2012.24045.
  • 14. Ito CA, Gales AC, Tognim MC, Munerato P, Dalla Costa LM. Quinolone-resistant Escherichia coli. Braz J Infect Dis. 2008;12(1):5-9. doi: 10.1590/S1413-86702008000100003. [PubMed: 18553006].
  • 15. Shigemura K, Tanaka K, Yamamichi F, Shirakawa T, Miyake H, Fujisawa M. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study. Int J Antimicrob Agents. 2012;40(6):516-20. doi: 10.1016/j.ijantimicag.2012.07.019. [PubMed: 23068598].
  • 16. Fabrega A, Madurga S, Giralt E, Vila J. Mechanism of action of and resistance to quinolones. Microb Biotechnol. 2009;2(1):40-61. doi: 10.1111/j.1751-7915.2008.00063.x. [PubMed: 21261881].
  • 17. Fauci AS, Braunwald E, Kasper DL. Harrison's principles of internal medicine. 17th ed. USA: McGraw-Hill; 2008.
  • 18. Washington C, Stephen A, Janda W. Koneman's color atlas and textbook of diagnostic microbiology. 6th ed. USA: Lippincott williams & wilkins; 2006.
  • 19. Clinical and Laboratory Standards Institute . Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. Wayne, PA, USA: CLSI; 2012.
  • 20. Komp Lindgren P, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother. 2003;47(10):3222-32. doi: 10.1128/AAC.47.10.3222-3232.2003. [PubMed: 14506034].
  • 21. Park YH, Yoo JH, Huh DH, Cho YK, Choi JH, Shin WS. Molecular analysis of fluoroquinolone-resistance in Escherichia coli on the aspect of gyrase and multiple antibiotic resistance (mar) genes. Yonsei Med J. 1998;39(6):534-40. doi: 10.3349/ymj.1998.39.6.534. [PubMed: 10097680].
  • 22. Raei F, Eftekhar F, Feizabadi MM. Prevalence of Quinolone Resistance Among Extended-Spectrum beta -Lactamase Producing Uropathogenic Klebsiella pneumoniae. Jundishapur J Microbiol. 2014;7(6). e10887. doi: 10.5812/jjm.10887. [PubMed: 25371807].
  • 23. Hsueh PR. Study for Monitoring Antimicrobial Resistance Trends (SMART) in the Asia-Pacific region, 2002-2010. Int J Antimicrob Agents. 2012;40 Suppl:S1-3. doi: 10.1016/S0924-8579(12)00244-0. [PubMed: 22749052].
  • 24. Pakzad I, Ghafourian S, Taherikalani M, Sadeghifard N, Abtahi H, Rahbar M, et al. qnr Prevalence in Extended Spectrum Beta-lactamases (ESBLs) and None-ESBLs Producing Escherichia coli Isolated from Urinary Tract Infections in Central of Iran. Iran J Basic Med Sci. 2011;14(5):458-64. [PubMed: 23493061].
  • 25. Lagace-Wiens PR, Nichol KA, Nicolle LE, Decorby MR, McCracken M, Alfa MJ, et al. ESBL genotypes in fluoroquinolone-resistant and fluoroquinolone-susceptible ESBL-producing Escherichia coli urinary isolates in Manitoba. Can J Infect Dis Med Microbiol. 2007;18(2):133-7. doi: 10.1155/2007/848194. [PubMed: 18923714].
  • 26. Hassan WM, Hashim A, Domany R. Plasmid mediated quinolone resistance determinants qnr, aac(6')-Ib-cr, and qep in ESBL-producing Escherichia coli clinical isolates from Egypt. Indian J Med Microbiol. 2012;30(4):442-7. doi: 10.4103/0255-0857.103766. [PubMed: 23183470].
  • 27. Alheib O, Al Kayali R, Abajy MY. Prevalence of plasmid-mediated quinolone resistance (PMQR) determinants among extended spectrum beta-lactamases (ESBL)-producing isolates of escherichia coli and klebsiella pneumoniae in Aleppo, Syria. Arch Clin Infect Dis. 2015;10(3). doi: 10.5812/archcid.20631.
  • 28. Soleimani-Asl Y, Zibaei M, Firoozeh F. Detection of qnrA gene among quinolone-resistant Escherichia coli isolated from urinary tract infections in Khorram Abad during 2011-2012 [In Persian]. Feyz. 2013;17(5):488-94.
  • 29. Mansouri Jamshidi N, Pakzad I, Tabaraei B. Evaluating the frequency of ciprofloxacin resistance qnr genes in escherichia coli strains isolated from clinical samples of Imam Khomani and Milad Hospitals in Ilam and Tehran, Iran [In Persian]. J Ilam Univ Med Sci. 2012;21(6):16-22.
  • 30. Shibl AM, Radwa HH.Al-Agamy. Detection of mutations in quinolone-resistant determining regions in clinical isolates of Escherichia coli from Saudi Arabia. Afr J Biotechnol. 2012;11(5):1054-8.
  • 31. Piddock LJ. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs. 1999;58 Suppl 2:11-8. doi: 10.2165/00003495-199958002-00003. [PubMed: 10553699].
  • 32. Abdi-Hachesoo B, Asasi K, Sharifiyazdi H. Rapid detection of Escherichia coli gyrA and parC mutants in one-day-old broiler chicks in Iran. Vet Ital. 2013;49(3):291-7. [PubMed: 24358491].
  • 33. Ardebili A, Lari AR, Beheshti M, Lari ER. Association between mutations in gyrA and parC genes of Acinetobacter baumannii clinical isolates and ciprofloxacin resistance. Iran J Basic Med Sci. 2015;18(6):623-6. [PubMed: 26221488].
  • 34. Liu BT, Liao XP, Yang SS, Wang XM, Li LL, Sun J, et al. Detection of mutations in the gyrA and parC genes in Escherichia coli isolates carrying plasmid-mediated quinolone resistance genes from diseased food-producing animals. J Med Microbiol. 2012;61(Pt 11):1591-9. doi: 10.1099/jmm.0.043307-0. [PubMed: 22878251].
  • 35. Weigel LM, Steward CD, Tenover FC. gyrA mutations associated with fluoroquinolone resistance in eight species of Enterobacteriaceae. Antimicrob Agents Chemother. 1998;42(10):2661-7. [PubMed: 9756773].
  • 36. Vila J, Ruiz J, Goni P, De Anta MT. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother. 1996;40(2):491-3. [PubMed: 8834907].
  • 37. Hopkins KL, Davies RH, Threlfall EJ. Mechanisms of quinolone resistance in Escherichia coli and Salmonella: recent developments. Int J Antimicrob Agents. 2005;25(5):358-73. doi: 10.1016/j.ijantimicag.2005.02.006. [PubMed: 15848289].
  • 38. Al-Marzooq F, Mohd Yusof MY, Tay ST. Molecular analysis of ciprofloxacin resistance mechanisms in Malaysian ESBL-producing Klebsiella pneumoniae isolates and development of mismatch amplification mutation assays (MAMA) for rapid detection of gyrA and parC mutations. Biomed Res Int. 2014;2014:601630. doi: 10.1155/2014/601630. [PubMed: 24860827].
  • 39. Ogbolu DO, Daini OA, Ogunledun A. Effects of gyrA and parC mutations in quinolones resistant clinical gram negative bacteria from Nigeria. Afr J Biomed Res. 2012;15(2):97-104.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments